Key clinical point: Inhaled treprostinil may improve symptoms of pulmonary hypertension in interstitial lung disease.

Major finding: Treprostinil was associated with a median 21-m improvement in 6-minute walk distance.

Study details: A phase 3, randomized, placebo-controlled trial in 326 patients.

Disclosures: The study was funded by United Therapeutics. Dr. Nathan disclosed advisory committee activity/consulting, research support, and speaker fees from the company. Dr. Kolb has previously disclosed financial relationships with various companies, not including United Therapeutics.